$AWHL · Aspira Women's Health Inc.
Aspira Women's Health filed its 10-Q for the quarter ended September 30, 2026. Revenue fell 18.4% YoY to $1.9M, with OvaSuite test volume down 13% to 14,870 tests. The company reported net income of $339,000 for the quarter, driven by a $1.9M non-cash gain on warrant liability fair value, but a nine-month net loss of $1.4M. Cash and cash equivalents collapsed to $12,000 from $1.755M at year-end, and the company disclosed a going-concern warning.
- Cash and cash equivalents fell to $12,000 from $1.755M at December 31, 2025.
- Q3 revenue of $1.9M declined 18.4% YoY; OvaSuite test volume fell 13% to 14,870.
- Nine-month net loss was $1.4M, improved from $9.4M a year earlier.
- Q3 net income of $339,000 stemmed from a $1.9M non-cash warrant liability fair-value gain.
- Working capital deficit was with an accumulated deficit of $545.6M.
Price data unavailable.
A diagnostics company with $12,000 in cash and a going-concern warning faces an acute liquidity crisis despite a headline quarterly profit.
Aspira's shrinking OvaSuite volume contrasts with broader diagnostics growth, underscoring its liquidity-driven survival challenge.
Going-concern disclosure cites $12,000 cash, $4.2M working capital deficit, and expected continued losses and negative operating cash flow for the rest of 2026.